Table 1.
Demographic, clinical characteristics, and treatments of 400 patients with SLE
| Characteristics | |
|---|---|
| Sex (female) | 372 (93.0) |
| Mean age at the moment of study (years) | 50.7 (49.5–52.1) |
| Duration of SLE (years) | 19.5 (18.5–20.5) |
| Lupus low disease activity state* | 352 (88.0) |
| Complete remission† | 82 (20.6) |
| SLEDAI | 2.2 (2.0–2.4) |
| SDI | 0.9 (0.8–1.1) |
| Treatments | |
| Hydroxychloroquine | 291 (72.9) |
| Mepacrine | 9 (2.3) |
| Any antimalarial | 296 (74.2) |
| Prednisone | 203 (50.9) |
| Mean dose of prednisone (mg/day) | 2.3 (2.0–2.7) |
| Immunosuppressants | 223 (55.9) |
| Mycophenolate | 56 (14.0) |
| Azathioprine | 35 (8.8) |
| Methotrexate | 24 (6.0) |
| Tacrolimus | 12 (3.0) |
| Biologics ‡ (rituximab or belimumab) | 14 (3.5) |
| Belimumab (ongoing) | 11 (2.8) |
| Rituximab (in the last 6 months) | 3 (0.8) |
| Immunosuppressants and biologics | 14 (3.5) |
| Antiaggregant | 105 (26.4) |
| Anticoagulation | 62 (15.5) |
| Epidemiological data | |
| Times per week that you left your home during lockdown | 1.9 (1.6–2.2) |
| COVID-19 contact (yes) | 42 (10.5) |
| Number of people with whom you live | 1.8 (1.7–1.9) |
Quantitative variables are expressed as mean (95%CI) and qualitative variables are expressed as number (percentage)
SDI, SLICC damage index; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; 95%CI, 95% confidence interval
*Lupus low disease activity state: SLEDAI-2K ≤ 4, allowing the patient to be on treatment with ≤ 7.5 mg/day of prednisolone and/or well-tolerated standard doses of immunosuppressive drugs
†Complete remission: SLEDAI-2K = 0 in corticosteroid-free and immunosuppressant-free patients; antimalarials were allowed
‡Including rituximab and belimumab